Financial
FY2025 revenue SEK 73.4m (-8.7%); net loss SEK 21.9m.
EBITDA SEK -15.9m; raised about SEK 52m in a rights issue.
Ortivus
HQ Sweden · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Weak
Customer rating
No reviews yet
Financial health
Band: WeakListed: ORTI-B.ST
FY2025 revenue SEK 73.4m (-8.7%); net loss SEK 21.9m.
EBITDA SEK -15.9m; raised about SEK 52m in a rights issue.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | SEK 73.4m | -8.7% | — | -SEK 21.9m | Ortivus |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Ortivus found in HSH's search of the last 24 months.
Cyber & information governance
No cyber incidents involving Ortivus found in HSH's search of the last 24 months; a July 2023 cyber-attack that took its UK-hosted MobiMed ePR offline for some customers falls outside this window. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, MHRA field safety notices or regulator actions involving Ortivus found in HSH's search of the last 24 months.
Contract performance
Jun 2025: South Western Ambulance Service extended its MobiMed ePR contract by two years to June 2027 (SEK 27.7m); Northern Ireland Ambulance Service also announced a two-year extension that month.
Competitors
No competitors linked yet.